2019
Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection
O'Donnell MR, Padayatchi N, Daftary A, Orrell C, Dooley KE, Amico K, Friedland G. Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection. The Lancet HIV 2019, 6: e201-e204. PMID: 30846058, PMCID: PMC7155388, DOI: 10.1016/s2352-3018(19)30035-9.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisBedaquiline treatmentTuberculosis-HIVLow antiretroviral therapy adherencePotent new therapyAntiretroviral therapy initiationAntiretroviral therapy adherenceEfavirenz-containing regimensFixed-dose combinationAntiretroviral therapy switchMiddle-income settingsDaily nevirapineAdherence supportAntiretroviral resistanceAntiretroviral therapyHIV patientsTherapy initiationViral failureTherapy switchImproved survivalTherapy adherenceDrug interactionsNew therapiesHIVBedaquiline
2012
The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial.
Naidoo K, Yende-Zuma N, Padayatchi N, Naidoo K, Jithoo N, Nair G, Bamber S, Gengiah S, El-Sadr WM, Friedland G, Abdool Karim S. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Annals Of Internal Medicine 2012, 157: 313-24. PMID: 22944873, PMCID: PMC3534856, DOI: 10.7326/0003-4819-157-5-201209040-00004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAntibiotics, AntitubercularAnti-Retroviral AgentsCD4 Lymphocyte CountFemaleHIV InfectionsHumansImmune Reconstitution Inflammatory SyndromeImmunocompromised HostIncidenceKaplan-Meier EstimateMaleProspective StudiesRifampinRisk FactorsSeverity of Illness IndexTuberculosisConceptsImmune reconstitution inflammatory syndromeSequential treatment groupIncidence of IRISReconstitution inflammatory syndromeAntiretroviral therapy initiationART initiationTreatment groupsIRIS incidenceSAPiT trialInflammatory syndromeTherapy initiationTreatment initiationTuberculosis treatmentOpen-label clinical trialCells/LCo-infected patientsEarly ART initiationInitiation of ARTTuberculosis treatment initiationSmear-negative tuberculosisHigher hospitalization ratesWeeks of completionBaseline CD4Antituberculosis treatmentNonambulatory patients